Induction chemotherapy with docetaxel, 5-FU and CDDP (DFP) for advanced gastric cancer

Kazuyoshi Yamamoto, Yoshiyuki Fujiwara, Toshiro Nishida, Shuji Takiguchi, Kiyokazu Nakajima, Hiroshi Miyata, Makoto Yamasaki, Masaki Mori, Yuichiro Doki

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: The aim of this study was to evaluate the feasibility and efficacy of modified triplet chemotherapy with docetaxel, 5-fluorouracil and cisplatin as induction chemotherapy for advanced gastric cancer (AGC). Patients and Methods: Treatment-naive patients with AGC were eligible. The regimen consisted of 350 mg/m2/day 5-FU by continuous infusion on days 1 to 5, 10 mg/m2/day CDDP intravenously on days 1 to 5, and docetaxel at 60 mg/m2/day intravenously on day 1. After 2 cycles (each cycle consisted of 4 weeks), surgical resection was attempted, 2-4 weeks after the completion of the regimen. Results: Eighteen patients were enrolled. Adverse events included grade 3 anorexia and nausea in 16.7% and 11.1% and grade 4 leukocytopenia and neutropenia in 5.6% and 27.8%, respectively. The overall response rate was 44.4%. Surgery was conducted in 15 patients. The 1- and 3-year survival rates were 75.6% and 51.1%, respectively. Conclusion: The modified triplet combination therapy is effective and well tolerated by patients with AGC.

Original languageEnglish
Pages (from-to)4211-4215
Number of pages5
JournalAnticancer research
Volume29
Issue number10
Publication statusPublished - Oct 1 2009
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Induction chemotherapy with docetaxel, 5-FU and CDDP (DFP) for advanced gastric cancer'. Together they form a unique fingerprint.

  • Cite this

    Yamamoto, K., Fujiwara, Y., Nishida, T., Takiguchi, S., Nakajima, K., Miyata, H., Yamasaki, M., Mori, M., & Doki, Y. (2009). Induction chemotherapy with docetaxel, 5-FU and CDDP (DFP) for advanced gastric cancer. Anticancer research, 29(10), 4211-4215.